A phase I/II trial of BAY 43-9006 and gemcitabine in advanced solid tumors and in advanced pancreatic cancer

被引：0
|
作者：
Siu, LL
Takimoto, CH
Awada, A
Moore, MJ
Piccart, M
Poulin-Costello, M
Lathia, C
Petrenciuc, O
机构：
[1] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[2] Univ Texas, Hlth Sci Ctr, San Antonio, TX 78285 USA
[3] Inst Jules Bordet, B-1000 Brussels, Belgium
[4] Bayer Inc, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3059
引用
收藏
页码：209S / 209S
页数：1
相关论文
共 50 条
  • [41] Randomised phase III trial of the multikinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC)
    不详
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (02) : 287 - 287
  • [42] Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors
    Brell, Joanna M.
    Krishnamurthi, Smitha S.
    Rath, Linda
    Bokar, Joseph A.
    Savvides, Panayiotis
    Gibbons, Joseph
    Cooney, Matthew M.
    Meropol, Neal J.
    Ivy, Percy
    Dowlati, Afshin
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (04) : 547 - 553
  • [43] Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors
    Reid, JM
    Qu, WC
    Safgren, SL
    Ames, MM
    Krailo, MD
    Seibel, NL
    Kuttesch, J
    Holcenberg, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) : 2445 - 2451
  • [44] Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors
    Joanna M. Brell
    Smitha S. Krishnamurthi
    Linda Rath
    Joseph A. Bokar
    Panayiotis Savvides
    Joseph Gibbons
    Matthew M. Cooney
    Neal J. Meropol
    Percy Ivy
    Afshin Dowlati
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 547 - 553
  • [45] Phase I trial of sorafenib (BAY 43-9006) combined with dacarbazine (DTIC) in patients with metastatic melanoma
    Eisen, T.
    Ahmad, T.
    Marais, R.
    Gibbens, I.
    James, M.
    Affolter, A.
    Chao, D.
    Bergamini, L.
    Schwartz, B.
    Gore, M. E.
    EJC SUPPLEMENTS, 2005, 3 (02): : 349 - 349
  • [46] A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer
    Chen, Justin A.
    Huynh, Jasmine C.
    Wu, Chun-Yi
    Yu, Ai-Ming
    Matsukuma, Karen
    Semrad, Thomas J.
    Gandara, David R.
    Li, Tianhong
    Riess, Jonathan W.
    Tam, Kit
    Mack, Philip C.
    Martinez, Anthony
    Mahaffey, Nichole
    Kelly, Karen L.
    Kim, Edward J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 90 (03) : 217 - 228
  • [47] A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer
    Justin A. Chen
    Jasmine C. Huynh
    Chun-Yi Wu
    Ai-Ming Yu
    Karen Matsukuma
    Thomas J. Semrad
    David R. Gandara
    Tianhong Li
    Jonathan W. Riess
    Kit Tam
    Philip C. Mack
    Anthony Martinez
    Nichole Mahaffey
    Karen L. Kelly
    Edward J. Kim
    Cancer Chemotherapy and Pharmacology, 2022, 90 : 217 - 228
  • [48] Clinical synergism from combinatorial VEGF signal transduction inhibition in patients with advanced solid tumors - early results from a phase I study of sorafenib (BAY 43-9006) and bevacizumab
    Posadas, E.
    Kwitkowski, V.
    Lie, M.
    Kotz, H.
    Minasian, L.
    Sarosy, G.
    Harold, N.
    Fioravanti, S.
    Kohn, E.
    EJC SUPPLEMENTS, 2005, 3 (02): : 419 - 420
  • [49] Prospective study of positron emission tomography evaluating the activity of sorafenib (BAY 43-9006) in patients with advanced tumors.
    Kawada, K
    Murakami, K
    Sato, T
    Kojima, Y
    Ebi, H
    Kitagawa, K
    Kim, Y
    Araki, K
    Mukai, H
    Tahara, M
    Nakajima, H
    Nakajima, K
    Minami, H
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9062S - 9062S
  • [50] A phase I pharmacokinetic and pharmacodynamic study of the raf kinase inhibitor BAY 43-9006 given orally to patients with solid tumors.
    Strumberg, D
    Bauer, RJ
    Moeller, JG
    Hilger, R
    Diaz-Carballo, D
    Richly, H
    Kredtke, S
    Beling, C
    Faghih, M
    Heinig, R
    Hedley, D
    Scheulen, ME
    Seeber, S
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3711S - 3711S
12345